| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Ngaihang Victor Chong | Q50636047 |
| Philip J. Luthert | Q42735745 | ||
| P2093 | author name string | C S Sethi | |
| T A Bailey | |||
| P2860 | cites work | Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha | Q24319999 |
| Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye | Q24625311 | ||
| Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1 | Q27742927 | ||
| A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells | Q28119154 | ||
| Evaluation of some newer matrix metalloproteinases | Q28140362 | ||
| Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy | Q28236562 | ||
| Cloning of the cDNA encoding human tissue inhibitor of metalloproteinases-3 (TIMP-3) and mapping of the TIMP3 gene to chromosome 22 | Q28253848 | ||
| Matrix metalloproteinases: structures, evolution, and diversification | Q28282370 | ||
| Negative regulation of gene expression by TGF-beta | Q28288541 | ||
| Night blindness in Sorsby's fundus dystrophy reversed by vitamin A | Q28288733 | ||
| Metalloproteinases and their inhibitors in matrix remodeling | Q28305537 | ||
| Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials | Q28369525 | ||
| Discovery and analysis of inflammatory disease-related genes using cDNA microarrays | Q28379596 | ||
| Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells | Q28581437 | ||
| Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release | Q28611028 | ||
| Matrix metalloproteinase degradation of extracellular matrix: biological consequences | Q28611041 | ||
| Identification and characterization of the fifth membrane-type matrix metalloproteinase MT5-MMP. | Q30656169 | ||
| Laser-induced drusen reduction improves visual function at 1 year. Choroidal Neovascularization Prevention Trial Research Group | Q30734509 | ||
| TIMP-1 expression is increased in X-linked progressive retinal atrophy despite its exclusion as a candidate gene | Q31916357 | ||
| The production of tissue inhibitors of metalloproteinases (TIMPs) in megakaryopoiesis: possible role of platelet- and megakaryocyte-derived TIMPs in bone marrow fibrosis | Q33500733 | ||
| Matrix metalloproteinase inhibitors | Q33538437 | ||
| The role of the mesangial cell and its matrix in the pathogenesis of diabetic nephropathy. | Q33547336 | ||
| Matrix-degrading proteases and angiogenesis during development and tumor formation. | Q33586429 | ||
| Proteolytic control of growth factor availability | Q33586464 | ||
| Matrilysin in early stage intestinal tumorigenesis | Q33586483 | ||
| Membrane-type matrix metalloproteinases | Q33586502 | ||
| Clinical studies with matrix metalloproteinase inhibitors | Q33586513 | ||
| Matrix metalloproteinases and their inhibitors in tumour growth and invasion | Q33603385 | ||
| Regulation of matrix metalloproteinase expression in tumor invasion. | Q33605726 | ||
| A second independent Tyr168Cys mutation in the tissue inhibitor of metalloproteinases-3 (TIMP3) in Sorsby's fundus dystrophy | Q33683363 | ||
| Matrix metalloproteinases in inflammatory demyelination: targets for treatment | Q33688698 | ||
| Role of matrix metalloproteinases and their inhibition in cutaneous wound healing and allergic contact hypersensitivity | Q33692891 | ||
| Tissue inhibitors of matrix metalloproteinases in cancer. | Q33692913 | ||
| Scientific basis of a matrix metalloproteinase-8 specific chair-side test for monitoring periodontal and peri-implant health and disease. | Q33692917 | ||
| Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications | Q33692926 | ||
| MMP inhibition in prostate cancer | Q33692934 | ||
| Matrix metalloproteinase inhibition. From the Jurassic to the third millennium | Q33692943 | ||
| Proteolysis and cell migration: creating a path? | Q33744936 | ||
| Extracellular matrix remodelling and cellular differentiation | Q33744976 | ||
| Differential expression of tissue inhibitors of metalloproteinases (TIMP-1, -2, -3, and -4) in normal and aberrant wound healing | Q33845541 | ||
| Immune modulation of metalloproteinase production in human macrophages. Selective pretranslational suppression of interstitial collagenase and stromelysin biosynthesis by interferon-gamma | Q34261766 | ||
| Expression of matrix metalloproteinase-2 and -9 during early human wound healing | Q34338048 | ||
| Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity | Q34457597 | ||
| Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins | Q34479986 | ||
| A fundus dystrophy with unusual features | Q34728881 | ||
| Accumulation of tissue inhibitor of metalloproteinases-3 in human eyes with Sorsby's fundus dystrophy or retinitis pigmentosa | Q35303077 | ||
| Stromelysin 3: an independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression | Q35765020 | ||
| Tissue inhibitor of metalloproteinases-3 is a component of Bruch's membrane of the eye. | Q35765321 | ||
| Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis | Q35785934 | ||
| Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer--a predictor of tumour stage | Q36431093 | ||
| Gelatinase B modulates selective opening of the blood-brain barrier during inflammation. | Q47918271 | ||
| Localization of the functional domains of human tissue inhibitor of metalloproteinases-3 and the effects of a Sorsby's fundus dystrophy mutation | Q47921791 | ||
| Matrix metalloproteinases and tissue inhibitors of metalloproteinases in viral meningitis: upregulation of MMP-9 and TIMP-1 in cerebrospinal fluid | Q47969608 | ||
| Matrix metalloproteinases and their inhibitors in human vitreous. | Q47994526 | ||
| Increase in interphotoreceptor matrix gelatinase A (MMP-2) associated with age-related macular degeneration | Q48585561 | ||
| Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. | Q48841710 | ||
| Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. | Q50849840 | ||
| Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. | Q50862383 | ||
| Exclusion of TIMP3 as a candidate locus in age-related macular degeneration. | Q50955711 | ||
| A matrix metalloproteinase inhibitor which prevents fibroblast-mediated collagen lattice contraction. | Q52866271 | ||
| Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood. | Q52998883 | ||
| Expression of vascular endothelial growth factor related to 72-kilodalton metalloproteinase immunostaining in patients with serous ovarian tumors. | Q53346120 | ||
| Clinical trials of a matrix metalloproteinase inhibitor in human periodontal disease. SDD Clinical Research Team. | Q53830014 | ||
| Epidermal expression of collagenase delays wound-healing in transgenic mice. | Q53940693 | ||
| Expression of matrix metalloproteinases and inhibitor by human retinal pigment epithelium. | Q54738198 | ||
| Analysis of coding sequences for tissue inhibitor of metalloproteinases 1 (TIMP1) and 2 (TIMP2) in patients with aneurysms | Q57783985 | ||
| Temporal activity of plasminogen activators and matrix metalloproteinases during cutaneous wound repair | Q60152145 | ||
| Predominance of MMP-1 and MMP-2 in Epiretinal and Subretinal Membranes of Proliferative Vitreoretinopathy | Q63407549 | ||
| Metalloproteinases and TIMP-1 in proliferative vitreoretinopathy | Q63407854 | ||
| Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B | Q64381924 | ||
| Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells | Q67590241 | ||
| Age-related macular degeneration | Q69037879 | ||
| Immunolocalization of collagenase and tissue inhibitor of metalloproteinases (TIMP) in hypertrophic scar tissue | Q70153180 | ||
| Cytokines cause cultured retinal pigment epithelial cells to secrete metalloproteinases and to contract collagen gels | Q70499002 | ||
| Proteinases in subretinal fluid | Q71293446 | ||
| Patterns of matrix metalloproteinase and TIMP-1 expression in chronic and normally healing human cutaneous wounds | Q71452998 | ||
| Temporal study of the activity of matrix metalloproteinases and their endogenous inhibitors during wound healing | Q71677554 | ||
| Long-term outcomes after the surgical removal of advanced subfoveal neovascular membranes in age-related macular degeneration. | Q36675477 | ||
| Optical coherence tomography of age-related macular degeneration and choroidal neovascularization | Q36814558 | ||
| The regulation of connective tissue metalloproteinases by natural inhibitors | Q36932264 | ||
| Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. | Q37486259 | ||
| Metalloproteinases and tissue damage. | Q37632520 | ||
| Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment | Q39713018 | ||
| Age-related macular disease | Q39714871 | ||
| Matrix metalloproteinase family | Q40441858 | ||
| Structural biochemistry and activation of matrix metalloproteases | Q40780363 | ||
| A prospective study of matrix metalloproteinases in proliferative vitreoretinopathy. | Q40851769 | ||
| Matrix metalloproteinase inhibitors in the treatment of cancer | Q40901330 | ||
| Human mast cells produce matrix metalloproteinase 9. | Q40933819 | ||
| Interleukin-1 alpha and basic fibroblast growth factor induction of matrix metalloproteinases and their inhibitors in osteosarcoma cells is modulated by the metastasis associated protein CAPL. | Q40986998 | ||
| Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. | Q41005189 | ||
| Host TIMP-1 overexpression confers resistance to experimental brain metastasis of a fibrosarcoma cell line | Q41035774 | ||
| Matrix metalloproteinases and metastatic cancer. | Q41056968 | ||
| Mechanisms controlling the transcription of matrix metalloproteinase genes in normal and neoplastic cells | Q41105683 | ||
| Different roles for plasminogen activators and metalloproteinases in melanoma metastasis. | Q41117132 | ||
| Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. | Q41151120 | ||
| Prognostic parameters in uveal melanoma: a review | Q41273822 | ||
| Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor | Q41343795 | ||
| Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). | Q41445433 | ||
| Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor | Q41447978 | ||
| The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical application | Q41451362 | ||
| Relating matrix metalloproteinase structure to function: why the "hemopexin" domain? | Q41460643 | ||
| Mighty mice: transgenic technology "knocks out" questions of matrix metalloproteinase function | Q41460657 | ||
| A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth | Q41481835 | ||
| The regulation of neovascularization of matrix metalloproteinases and their inhibitors | Q41487215 | ||
| Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. | Q41628042 | ||
| Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum | Q41639433 | ||
| Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat | Q41639826 | ||
| Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation | Q41643679 | ||
| Physiological mechanisms for metalloproteinase activation | Q41647723 | ||
| Gene therapy for inherited retinal degeneration | Q41677858 | ||
| Matrix metalloproteinases in skin | Q41694093 | ||
| Analysis of gene expression in human bullous keratopathy corneas containing limiting amounts of RNA. | Q41705744 | ||
| Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 in the retinal pigment epithelium and interphotoreceptor matrix: vectorial secretion and regulation | Q42444475 | ||
| Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues | Q42603394 | ||
| Evaluation of the gene encoding the tissue inhibitor of metalloproteinases-3 in various maculopathies | Q42656114 | ||
| Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix | Q43755354 | ||
| Matrix metalloproteinase-2 (MMP-2) immunoreactive protein--a new prognostic marker in uveal melanoma? | Q44901177 | ||
| MMP-8 is the predominant collagenase in healing wounds and nonhealing ulcers | Q45116102 | ||
| Sequential activation and production of matrix metalloproteinase-2 during breast cancer progression | Q45880087 | ||
| Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases | Q46699016 | ||
| Matrix metalloproteinase expression in human retinal microvascular cells | Q47690714 | ||
| Localization of matrix metalloproteinases-1, -2, and -9 and tissue inhibitor of metalloproteinase-2 in interstitial lung diseases. | Q47913987 | ||
| Surgery for subfoveal membranes in myopia, angioid streaks, and other disorders | Q71766694 | ||
| Metalloproteinases in the rheumatic diseases | Q71928745 | ||
| Interleukin-1-beta changes the expression of metalloproteinases in the vitreous humor and induces membrane formation in eyes containing preexisting retinal holes | Q71991213 | ||
| Tissue inhibitor of metalloproteinases‐2 inhibits bFGF‐induced human microvascular endothelial cell proliferation | Q72102660 | ||
| Regulation of tissue inhibitor of matrix metalloproteinase expression | Q72853147 | ||
| Age-dependent variation in metalloproteinase activity of isolated human Bruch's membrane and choroid | Q73049085 | ||
| Expression of matrix metalloproteinase-7 in choroidal neovascular membranes in age-related macular degeneration | Q73052540 | ||
| Cytokine and chemokine regulation of proMMP-9 and TIMP-1 production by human peripheral blood lymphocytes | Q73082091 | ||
| Discrete expression and distribution pattern of TIMP-3 in the human retina and choroid | Q73152478 | ||
| Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3 | Q73252853 | ||
| A gene delivery system activatable by disease-associated matrix metalloproteinases | Q73254121 | ||
| TIMP-3, collagen, and elastin immunohistochemistry and histopathology of Sorsby's fundus dystrophy | Q73535482 | ||
| KB-R7785, a novel matrix metalloproteinase inhibitor, exerts its antidiabetic effect by inhibiting tumor necrosis factor-alpha production | Q73635302 | ||
| Membrane type-1 matrix metalloproteinase in human ocular tissues | Q73676945 | ||
| Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma | Q73828612 | ||
| An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy | Q74100089 | ||
| Regulation of distinct steps of angiogenesis by different angiogenic molecules | Q74306399 | ||
| Matrix metalloproteinases and metalloproteinase inhibitors in human interphotoreceptor matrix and vitreous | Q74382371 | ||
| Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts | Q74440366 | ||
| Immunolocalization of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human subconjunctival tissues | Q74485009 | ||
| Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes | Q74586672 | ||
| Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-alpha, granulocyte-macrophage CSF, and IL-1 beta through prostaglandin-dependent and -independent mechanisms | Q77319343 | ||
| Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor | Q77334697 | ||
| Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes | Q77372480 | ||
| Matrix metalloproteinase matrilysin (MMP-7) participates in the progression of human gastric and esophageal cancers | Q77410279 | ||
| Complex role of matrix metalloproteinases in angiogenesis | Q77474882 | ||
| TIMP-1 and TIMP-2 levels in vitreous and subretinal fluid | Q77581908 | ||
| Localization and translocation of MMP-2 during aggregation of human platelets | Q77647789 | ||
| New discoveries on the roles of matrix metalloproteinases in ocular cell biology and pathology | Q77695542 | ||
| Presence of four tissue inhibitors of matrix metalloproteinases (TIMP-1, -2, -3 and -4) in human fetal membranes | Q77812444 | ||
| ProMMP-9 (92 kDa gelatinase) in vitreous fluid of patients with proliferative diabetic retinopathy | Q77899869 | ||
| Experimental models to identify antimetastatic drugs: are we there yet? A position paper | Q78027252 | ||
| MMP-mediated events in diabetes | Q78027264 | ||
| Regulation of TIMP-1 expression by hypoxia in kidney fibroblasts | Q78027312 | ||
| MMPs are IGFBP-degrading proteinases: implications for cell proliferation and tissue growth | Q78027491 | ||
| TIMP-3 in Bruch's membrane: changes during aging and in age-related macular degeneration | Q78221848 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 13 | |
| P304 | page(s) | 654-666 | |
| P577 | publication date | 2000-06-01 | |
| P1433 | published in | British Journal of Ophthalmology | Q13443571 |
| P1476 | title | Matrix metalloproteinase biology applied to vitreoretinal disorders | |
| P478 | volume | 84 |
| Q43578088 | Analysis of matrix dynamics by atomic force microscopy |
| Q36266395 | Bruch's membrane and the vascular intima: is there a common basis for age-related changes and disease? |
| Q92797411 | CLIC4 regulates late endosomal trafficking and matrix degradation activity of MMP14 at focal adhesions in RPE cells |
| Q36189122 | Effect of bradykinin on TGF-β1-induced retinal pigment epithelial cell proliferation and extracellular matrix secretion |
| Q38536307 | Effects of doxycycline on intestinal ischemia reperfusion injury induced by abdominal compartment syndrome in a rat model |
| Q35592840 | Elevated aqueous humour tissue inhibitor of matrix metalloproteinase-1 and connective tissue growth factor in pseudoexfoliation syndrome. |
| Q46852214 | Epigalloccatechin-3-gallate inhibits ocular neovascularization and vascular permeability in human retinal pigment epithelial and human retinal microvascular endothelial cells via suppression of MMP-9 and VEGF activation |
| Q58217653 | Expression of matrix metalloproteinases in the subretinal fluid correlates with the extent of rhegmatogenous retinal detachment |
| Q37250409 | Functional and molecular characterization of ex vivo cultured epiretinal membrane cells from human proliferative diabetic retinopathy. |
| Q41287573 | Intraocular matrix metalloproteinase 2 and 9 in patients with diabetes mellitus with and without diabetic retinopathy |
| Q35591037 | Is granuloma annulare related to intermediate uveitis with retinal vasculitis? |
| Q34485501 | Is the corneal degradation in keratoconus caused by matrix-metalloproteinases? |
| Q34572802 | MMPs in the eye: emerging roles for matrix metalloproteinases in ocular physiology. |
| Q37581458 | Matrix Metallopeptidase-2 Gene rs2287074 Polymorphism is Associated with Brick Tea Skeletal Fluorosis in Tibetans and Kazaks, China |
| Q58217617 | Matrix metalloproteinase (MMP-2, -9) and tissue inhibitor (TIMP-1, -2) activity in tear samples of pediatric type 1 diabetic patients |
| Q41912842 | Matrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-2, and transforming growth factor beta 1 in the aqueous humor and serum of patients with pseudoexfoliation syndrome |
| Q34674433 | Matrix metalloproteinases in disease and repair processes in the anterior segment. |
| Q36634707 | Polymorphisms in matrix metalloproteinases MMP1 and MMP9 are associated with primary open-angle and angle closure glaucoma in a Pakistani population. |
| Q31101634 | Preventive versus treatment effect of AG3340, a potent matrix metalloproteinase inhibitor in a rat model of choroidal neovascularization |
| Q34572836 | Proliferative vitreoretinopathy: risk factors and pathobiology |
| Q46432753 | Retinal vascular development and pathologic retinal angiogenesis are not impaired in matrix metalloproteinase-2 deficient mice |
| Q35688919 | Retinopathy in juvenile diabetes: a 10-year (1990-2000) review |
| Q50858315 | The Effect of Everolimus on Scar Formation in Glaucoma Filtering Surgery in a Rabbit Model. |
| Q54266323 | The role of MMP2 (-1306C>T) and TIMP2 (-418 G>C) promoter variants in age-related macular degeneration. |
| Q34550279 | Transcription Factors Pax6 and AP-2alpha Interact To Coordinate Corneal Epithelial Repair by Controlling Expression of Matrix Metalloproteinase Gelatinase B |
| Q36662676 | Vitreous TIMP-1 levels associate with neovascularization and TGF-β2 levels but not with fibrosis in the clinical course of proliferative diabetic retinopathy |
Search more.